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https://doi.org/10.1016/j.healun.2019.05.BACKGROUND: Chronic lung allograft dysfunction (CLAD) is the main limitation to long-term survival
after lung transplantation. Because effective therapies are lacking, early identification and mitigation
of risk factors is a pragmatic approach to improve outcomes. Acute cellular rejection (ACR) is the
most pervasive risk factor for CLAD, but diagnosis requires transbronchial biopsy, which carries risks.
We hypothesized that gene expression in the bronchoalveolar lavage (BAL) cell pellet (CP) could
replace biopsy and inform on mechanisms of CLAD.
METHODS: We performed RNA sequencing on BAL CPs from 219 lung transplant recipients with
A-grade ACR (n = 61), lymphocytic bronchiolitis (n = 58), infection (n = 41), or no rejection/infection
(n = 59). Differential gene expression was based on absolute fold difference >2.0 and Benjamini-
adjusted p-value ≤0.05. We used the Database for Annotation, Visualization and Integrated Discovery
Bioinformatics Resource for pathway analyses. For classifier modeling, samples were randomly split
into training (n = 154) and testing sets (n = 65). A logistic regression model using recursive feature
elimination and 5-fold cross-validation was trained to optimize area under the curve (AUC).
RESULTS: Differential gene expression identified 72 genes. Enriched pathways included T-cell receptor sig-
naling, natural killer cell−mediated cytotoxicity, and cytokine−cytokine receptor interaction. A 4-gene
model (AUC= 0.72) and classification threshold defined in the training set exhibited fair performance in
the testing set; accuracy was 76%, specificity 82%, and sensitivity 60%. In addition, classification as ACR
was associated with worse CLAD-free survival (hazard ratio = 2.42; 95% confidence interval = 1.29−4.53).
CONCLUSIONS: BAL CP gene expression during ACR is enriched for immune response pathways and
shows promise as a diagnostic tool for ACR, especially ACR that is a precursor of CLAD.
J Heart Lung Transplant 2019;38:845−855
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846 The Journal of Heart and Lung Transplantation, Vol 38, No 8, August 2019Lung transplant remains a viable treatment option for
select patients with advanced lung diseases, but long-term
outcomes remain disappointing. The main limitation to
better long-term survival is chronic lung allograft dys-
function (CLAD), which affects more than half of the
lung recipients by 5 years post-transplant.1 Currently,
there are no proven effective treatments. Therefore, pre-
ventive strategies are key, including risk factor identifica-
tion and mitigation. The principal risk factor for CLAD is
acute rejection or, more precisely, A-grade acute cellular
rejection (ACR), which is diagnosed by transbronchial
biopsy (TBBX) exhibiting perivascular mononuclear cell
infiltrates that can extend into the interstitium.2 Although
definitive data are lacking, it is widely accepted that treat-
ment of A-grade ACR with augmented immune suppres-
sion is an important strategy for reducing the risk of
CLAD. However, unnecessary treatment increases the
risk of opportunistic infections and malignancy, which
makes an accurate diagnosis important. Airway inflamma-
tion, also known as lymphocytic bronchiolitis (LB), is var-
iably also termed B-grade ACR.2 However, the frequent
coexistence with airway infection, as well as reported
refractoriness to corticosteroid treatment,3 are sources of
controversy for inclusion of LB as ACR.
Although considered the current gold standard, the
utility of TBBX to diagnose A-grade ACR is limited by
several factors. First, TBBX has been associated with a
4% incidence of pneumothorax and 3% incidence of
major bleeding.4 In lung transplant recipients specifi-
cally, the incidence of a major complication of bronchos-
copy was 2.3%, with TBBX being the major risk factor.5
Besides patient safety, TBBX is associated with a rela-
tively high rate of sampling error. In a recent multicenter
study, approximately 8% of TBBXs yielded an inade-
quate sample unable to be graded for A-grade ACR, and
another 26% were assessed as sub-optimal (fewer than 5
pieces of well-expanded alveolated lung).6 Even when
alveolated tissue is obtained, affected areas may be
missed by the relatively small volume of tissue sampled
by TBBX. Finally, there is well-described variability in
interobserver interpretation of TBBX for A-grade ACR,
with k values ranging from 0.183 to 0.479.6−8 Further-
more, the interobserver agreement for B-grade ACR, or
LB, was even worse, with k values ranging from ¡0.042
to 0.465.6−8 This limited ability to safely and reliably
diagnose ACR may affect clinicians’ ability to mitigate
risk and prevent CLAD.
Bronchoalveolar lavage (BAL) is routinely performed con-
currently with TBBX to rule out infection. As compared with
TBBX, BAL is safer and samples a relatively large area of the
lung. We hypothesized that gene expression in the BAL cell
pellet (CP) could replace TBBX for the diagnosis of ACR and
improve risk stratification for progression to CLAD. Partici-
pants in this study provided written informed consent for
enrollment in the University of California, Los Angeles
(UCLA) lung transplant outcomes registry and biorepository
approved by the UCLA institutional review board. This study
was sponsored by a Clinical Trials in Organ Transplant ancil-
lary studies grant.Methods
We have enrolled lung transplant recipients into the UCLA lung
transplant outcomes registry and biorepository study since 2001.
Lung recipients at UCLA undergo surveillance bronchoscopy at 1,
3, 6, and 12 months post-transplant and when clinically indicated.
We collected and banked any leftover BAL fluid from all surveil-
lance and “for cause” bronchoscopies.
The BAL procedure was performed according to a standard-
ized protocol using three 60-ml aliquots of isotonic saline
instilled into a sub-segmental bronchus of either the right middle
lobe or left lingula. Retrieved BAL fluid was pooled and then
split into a 15-ml clinical specimen and a research specimen with
the remaining volume. The research samples were immediately
placed on ice for transport to the lab and were processed within
6 hours of collection. BAL fluid was filtered through sterile
gauze, and cells were separated from fluid by centrifugation.
Cells were washed twice with phosphate-buffered saline and
lysed in TRIzol (Invitrogen, Carlsbad, CA).
TBBX specimens were graded for ACR by experienced tho-
racic pathologists according to the standard International Soci-
ety for Heart and Lung Transplantation criteria.2,9,10 Briefly,
peri-vascular (A-grade) infiltrates were scored 0−4. However,
before 2008, our pathologists only graded peri-airway infiltrates
(LB or B-grade) as absent (B0) or present (B1). In 2008, our
center adopted the revised nomenclature for B-grade rejection
(B0, B1R, and B2R). Because the specimens used in this study
span this change in nomenclature, we could only consider LB
as present or absent. Biopsy results were based upon chart
review of clinical read only. Slides were not re-reviewed. A-
grade ACR episodes were also categorized as either spirometri-
cally significant (SSAR) or non-SSAR based on a ≥10%
decline in forced expiratory volume in one second (FEV1) from
the baseline, defined as the highest of the 2 preceding FEV1
measurements, as described by Davis et al.11 A-grade ACR epi-
sodes without a paired FEV1 measurement between 0 and
14 days before the biopsy could not be classified as SSAR or
non-SSAR. CLAD was defined as a sustained drop in FEV1 by
at least 20% from the average of the 2 best post-transplant
measurements, consistent with published criteria.12 For each
potential CLAD case, we reviewed available clinical data to
exclude alternative causes of FEV1 decline other than CLAD.
We searched our biorepository for BAL CP samples, collected
before a diagnosis of CLAD or from patients who never developed
CLAD, who were paired with a TBBX graded for both A- and
B-grade rejection scores. Out of 1,548 pre-CLAD samples in our
repository, 660 did not have a paired TBBX and were excluded.
An additional 178 samples were excluded because the paired
biopsy was not gradable for A-grade (AX) (n = 12) or not gradable
for B-grade (BX) (n = 166) rejection. We identified a total of 710
eligible BAL samples from 310 patients. Samples were then cate-
gorized into the following groups: (1) healthy (n = 286) without A-
grade ACR, LB, or infection; (2) A-grade ACR (n = 114) defined
as A-grade of A1 or greater, with or without concurrent LB, and
without infection; (3) LB (n = 100) defined as the presence of small
airway inflammation without concurrent A-grade ACR or infection;
and (4) infection (n = 210) defined as a positive culture for a poten-
tial pathogen. Blinded to CLAD and mortality outcomes, we then
selected 65 samples each from the healthy, A-grade ACR, and LB
categories and 45 additional samples from the infection group for
RNA isolation. In addition, samples were selected to achieve rela-
tive balance across the following post-transplant time-frame win-
dows: 1 month (16−60 days post-transplant), 3 months (61
−135 days post-transplant), 6 months (136−270 days post-
Weigt et al. Gene Expression During Acute Rejection 847transplant), and 1 year or later (>271 days post-transplant). No
more than 1 sample per patient was included.
Total RNA was isolated using TRIzol/chloroform extraction,
resuspended in RNase-free water, and purified using the miR-
Neasy Mini kit (Qiagen Inc, Valencia, CA). RNA samples were
then bio-analyzed with the Agilent 2100 BioAnalyzer (Agilent
Technologies, Palo Alto, CA), and samples were excluded if RNA
quantity was too low (<100 ng) or if the RNA integrity number
indicated severe degradation (<3.0). This excluded 21 samples (6
healthy, 4 infection, 7 LB, and 4 A-grade ACR) for insufficient
quantity (n = 16) or for degraded RNA (n = 5).
RNA sequencing (RNASeq) libraries were prepared with Clon-
tech SMARTer Stranded Total RNASeq (Pico) Kit (Takara Bio,
Kusatsu, Japan). The key steps include first-strand synthesis, tem-
plate switching, adapter ligation, cleavage of ribosomal comple-
mentary DNA, and polymerase chain reaction amplification. The
library qualities were evaluated using the Agilent 2100 BioAna-
lyzer and then sequenced using Illumina Hiseq3000 (SR 1£ 50
run) (Illumina, San Diego, CA). After demultiplexing with Illu-
mina Bcl2fastq2 v 2.17 and initial data quality check with Illumina
SAV, the raw reads were mapped to the latest UCSC transcript set
using Bowtie2 version 2.1.0, and the gene expression level was
estimated using RSEM v1.2.15.Statistical methods
Bioconductor package LIMMA (linear models for microarray
data)13,14 (Bioconductor, Buffalo, NY) was used for differential
gene expression analysis for normalized log2-transformed counts
of RNASeq data. To avoid overinterpretation, we only included
genes with at least 1 read per million mapped reads in at least 30
samples. LIMMA was used in conjunction with voom, which
weighs the mean-variance relationship of the log-counts needed
for accurate generalized linear modeling. A candidate list of dif-
ferentially expressed genes were identified based on an absolute
fold change >2.0 and Benjamini−Hochberg adjusted p-value of
LIMMA’s moderated t-test (p < 0.05). For functional annotation
and pathway enrichment analysis, the candidate probes were ana-
lyzed in the Database for Annotation, Visualization and Integrated
Discovery (DAVID),15 and processes and pathways were selected
based on Benjamini−Hochberg adjusted p-values < 0.05.16
Principal component analysis (PCA)17 was used to visualize theFigure 1 Eligible and Included Samples (a) Sample selection flow diag
eligible samples in biorepository. ACR, acute cellular rejection; CLAD, chseparation of the 2 groups. Further unsupervised hierarchical clus-
tering of differentially expressed probes was done by applying the
Ward’s minimum variance criterion linkage method18 with
Euclidean distance and presented in a heatmap.
For the construction of a classification model, we first split
the 219 subjects randomly into a training set and a testing set
with a ratio of 70:30. We summarized subject characteristics as
means with standard deviation, medians with interquartile
ranges, or proportions. Characteristics were compared between
training and testing sets using Student’s t-test, Mann−Whitney,
Fisher’s exact, or chi-square testing as appropriate. A logistic
regression model was fit using recursive feature elimination
with 5-fold cross-validation to reduce the number of predictors
and thus achieve a parsimonious model.19 In the model fitting
process, a receiver operator characteristic area under the curve
(AUC) was the metric used for selecting the optimal model.
Threshold selection was based on model performance metrics
in the training set. We then validated the threshold in the test-
ing set. In addition, Cox proportional hazard models and
Kaplan−Meier curves were fit for CLAD-free survival and
compared between groups diagnosed with A-grade ACR on
biopsy vs all other clinical conditions, and between predicted
ACR vs no predicted ACR using the genomic classifier model.
Most statistical analyses were conducted using the Bioconduc-
tor suite of packages,20 and Package “caret”21 in the R statistical
software environment version 3.3.1.22 Kaplan−Meier analyses for
CLAD-free survival were performed using GraphPad Prism ver-
sion 6.05 for Windows (GraphPad Software, La Jolla, CA, www.
graphpad.com).
The data discussed in this publication are available in the Men-
deley Data open research data repository.Results
Patient characteristics
Of the 310 lung transplant recipients with eligible BAL sam-
ples, the final study cohort included 219 unique subjects with
1 BAL sample each (Figure 1). The clinical characteristics of
the 91 eligible patients from whom we did not include a sam-
ple were similar to the final study cohort (Table S1 in theram. (b) Distribution of included samples over time, relative to total
ronic lung allograft dysfunction; LB, lymphocytic bronchiolitis.
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org). By design, selected samples were enriched for later time
points post-transplant were more likely to have histopathology
positive for LB and A-grade ACR and were less likely to have
infection diagnosed or be healthy (Supplementary Table S2
online). In addition, the characteristics of samples excluded
for RNA quantity or quality were similar to the final studyTable 1 Characteristics of Subjects With A-Grade ACR and Other Histo
Total cohort
Characteristic
A-grade
ACR Other p-value
A-grade
ACR
Sex, n (%) 0.54
Male 40 (66) 96 (61) 30 (65
Female 21 (34) 62 (39) 16 (35
Age, mean (SD) 58.7 (11.0) 60.1 (11.3) 0.41 59.3 (11
Pre-transplant
disease, n (%)
0.80
Restrictive 38 (62) 92 (58) 27 (59
Obstructive 15 (25) 43 (27) 12 (26
CF/bronchiectasis 2 (3) 10 (6) 2 (4)
Other 6 (10) 13 (8) 5 (11
Transplant type, n (%) 0.76
Bilateral 34 (56) 84 (53) 25 (54
Single 27 (44) 74 (47) 21 (46
CMV serostatus, n (%) 0.41
R+/D+ 32 (52) 70 (44) 24 (52
R+/D- 14 (23) 32 (20) 10 (22
R-/D+ 8 (13) 36 (23) 7 (15
R-/D- 7 (12) 20 (13) 5 (11
Days to biopsy,
mean (SD)
170 (207) 230 (253) 0.10 157 (21
Indication for
biopsy, n (%)
0.85
Surveillance 49 (80) 124 (78) 38 (83
For cause 12 (20) 34 (22) 8 (17
Induction, n (%) 1.00
ATG 32 (52) 82 (52) 23 (50
Basiliximab 29 (48) 76 (48) 23 (50
Tacrolimus trough,
mean (SD)
10.6 (5.4) 9.9 (3.9) 0.32 10.7 (5.6
FEV1 % of baseline,
median (IQR)
100
(93−100)
99
(90−100)
0.06 100
(92−1
TBBX histopathology,
n (%)
.
A1 38 (62) . 29 (63
A2 17 (28) . 12 (26
A3 6 (10) . 5 (11
Lymphocytic
bronchiolitis
27 (44) 70 (44) 22 (48
Infection, n (%) . 41 (26) . .
Respiratory virusa . 10 (6) .
Bacterialb . 19 (12) .
Fungalc . 12 (8) .
ACR, acute cellular rejection; ATG, anti-thymocyte globulin; CF, cystic fibros
IQR, intraquartile range; SD, standard deviation; TBBX, transbronchial biopsy
a3 coronavirus, 3 parainfluenza, 2 rhinovirus, 1 respiratory syncytial virus, 1 in
b13 Pseudomonas aeruginosa, 3 Escherichia coli, 2 Haemophilus influenzae, 1 K
c8 Aspergillus fumigatus, 3 Aspergillus niger, 1 Aspergillus nidulanscohort,with the exception of the measures of RNA quan-
tity and quality (Supplementary Table S2 online). Among
the samples included in the final study cohort, the charac-
teristics of those with histopathologic A-grade ACR were
similar to those without A-grade ACR on biopsy (Table 1).
Training and testing sets were also similar (Supplementary
Table S3 online).pathology
Training set Test set
Other p-value
A-grade
ACR Other p-value
0.86 0.55
) 74 (62) 10 (67) 22 (56)
) 45 (38) 4 (33) 17 (44)
.1) 59.7 (11.4) 0.85 56.9 (10.9) 61.4 (10.8) 0.17
0.93 0.28
) 74 (62) 11 (73) 18 (46)
) 30 (25) 3 (20) 13 (33)
5 (4) 0 (0) 5 (13)
) 10 (8) 1 (7) 3 (8)
0.73 1.00
) 61 (51) 9 (60) 23 (59)
) 58 (49) 6 (40) 16 (41)
0.55 0.78
) 50 (42) 8 (53) 20 (51)
) 24 (20) 4 (27) 8 (21)
) 29 (24) 1 (7) 7 (18)
) 16 (13) 2 (13) 4 (10)
2) 235 (264) 0.07 213 (194) 216 (219) 0.96
1.00 1.00
) 97 (82) 11 (73) 27 (69)
) 22 (18) 4 (27) 12 (31)
0.61 0.37
) 65 (55) 9 (60) 17 (44)
) 54 (45) 6 (40) 22 (56)
) 10.1 (4.1) 0.46 10.5 (4.9) 9.5 (3.3) 0.45
00)
99
(90−100)
0.13 100
(95−100)
99
(88−100)
0.23
. .
) . 9 (60) .
) . 5 (33) .
) . 1 (7) .
) 52 (44) 5 (33) 18 (46)
34 (29) . . 7 (18)
8 (7) . 2 (5)
18 (15) . 1 (3)
8 (7) . 4 (10)
is; CMV, cytomegalovirus; FEV1, forced expiratory volume in one second;
fluenza A.
lebsiella pneumoniae
Figure 2 Volcano plot demonstrating gene expression in bronchoalveolar lavage (BAL) cell pellet (CP) from lung transplant recipients
with A-grade acute cellular rejection (ACR) compared with other non−A-grade ACR clinical conditions. Each dot on the graph corresponds
to a gene. The fold difference in expression between A-grade ACR and others is graphed on the x axis (logarithm to the base 2-fold
changes). The p-values for each gene are graphed on the y axis (negative logarithm to the base 10 of the t-test Benjamini−Hochberg
adjusted p-values). The vertical dashed lines correspond to absolute fold difference of -2.0 and 2.0. The horizontal dashed line corresponds
to a Benjamini-adjusted p-value of 0.05. Differentially expressed genes (n = 72) are labeled red (selected interesting genes are labeled with
official gene symbol as well). Additional black dots in the significance range (n = 5) represent chimera transcripts removed from the gene
list. No genes were expressed at significantly lower levels during A-grade ACR. UCLA, University of California, Los Angeles.
Weigt et al. Gene Expression During Acute Rejection 849Differential gene expression analyses
After removing the transcripts with low read count across
samples, 16,081 out of 25,343 transcripts remained. Dif-
ferential gene expression analysis identified 72 genes, all
of which were upregulated with A-grade ACR (Figure 2,
Table 2).
To get a visual impression of gene expression by patient
group, we performed PCA using the 72 differentially
expressed genes. The PCA demonstrated considerable over-
lap between A-grade ACR and other sample categories
(Supplementary Figure S1a online), which improved mod-
estly by focusing on A2 or greater ACR and healthy groups
(Supplementary Figure S1b online). Likewise, in unsuper-
vised hierarchical cluster analyses, A-grade ACR samples
tended to cluster together, but there was still considerable
misclassification (Supplementary Figure S1c online).Functional annotation and pathway enrichment
analyses
To test for and validate the biological relevance of the 72
differentially expressed genes, we compared functional
annotation and pathway mapping using DAVID Bioinfor-
matics Resources. Comparison of the biological process
category of gene ontology classification indicated that the
predominant processes associated with A-grade ACR
included immune response, adaptive immune response,
T-cell receptor (TCR) signaling pathway, and inflamma-
tory response (Table 3). Similarly, Kyoto Encyclopedia of
Genes and Genomes pathways significantly enriched in
this gene list included TCR signaling pathway, natural
killer (NK) cell−mediated cytotoxicity, cytokine−cyto-
kine receptor interactions, and allograft rejection, among
others (Table 4).
Table 2 Differentially Expressed Genes During ACR
Gene symbol FC p-value Adjusted p-value Gene symbol FC p-value Adjusted p-value
GZMK 2.99 0.0000 0.0030 TRAT1 2.30 0.0000 0.0035
KLRK1 2.98 0.0000 0.0020 TOX 2.30 0.0000 0.0040
IFNG 2.90 0.0000 0.0035 LINC00861 2.29 0.0000 0.0020
CXCL13 2.81 0.0004 0.0292 CD3E 2.29 0.0000 0.0082
GZMH 2.81 0.0000 0.0065 ITM2A 2.28 0.0001 0.0166
EOMES 2.77 0.0000 0.0030 TBX21 2.27 0.0002 0.0222
GZMA 2.76 0.0000 0.0035 ATP1A3 2.27 0.0000 0.0036
ZNF831 2.74 0.0000 0.0020 ITK 2.24 0.0000 0.0031
TIGIT 2.73 0.0000 0.0032 ZNF683 2.23 0.0004 0.0277
CXCR6 2.70 0.0000 0.0076 MS4A1 2.22 0.0007 0.0388
SIRPG 2.68 0.0000 0.0035 ETS1 2.22 0.0000 0.0042
CD8A 2.64 0.0000 0.0031 PRF1 2.21 0.0002 0.0224
MIAT 2.62 0.0000 0.0029 RASGRP1 2.20 0.0000 0.0030
FCRL3 2.56 0.0000 0.0030 GZMM 2.19 0.0001 0.0160
P2RY10 2.55 0.0000 0.0035 IL2RB 2.18 0.0001 0.0166
CD8B 2.55 0.0000 0.0038 UBASH3A 2.18 0.0001 0.0097
KLRC4 2.55 0.0000 0.0031 B3GAT1 2.16 0.0002 0.0183
FASLG 2.54 0.0000 0.0054 PDCD1 2.16 0.0009 0.0470
KLRC2 2.52 0.0000 0.0040 NKG7 2.15 0.0002 0.0224
SH2D2A 2.52 0.0000 0.0054 SAMD3 2.15 0.0002 0.0220
CTLA4 2.52 0.0000 0.0080 IL32 2.13 0.0001 0.0124
CXCR3 2.51 0.0000 0.0042 THEMIS 2.10 0.0000 0.0067
LAG3 2.50 0.0000 0.0042 NELL2 2.10 0.0003 0.0257
VCAM1 2.48 0.0001 0.0154 TSPAN5 2.10 0.0003 0.0250
GZMB 2.47 0.0003 0.0234 CPNE7 2.09 0.0001 0.0089
SH2D1A 2.46 0.0000 0.0043 APBA2 2.09 0.0003 0.0233
CD27 2.44 0.0000 0.0038 SLA2 2.09 0.0000 0.0054
GPR171 2.42 0.0000 0.0031 TMEM204 2.09 0.0001 0.0166
ZAP70 2.40 0.0000 0.0038 TTC24 2.07 0.0001 0.0130
LEF1 2.39 0.0000 0.0030 JAKMIP1 2.07 0.0008 0.0433
GPR174 2.38 0.0000 0.0041 GRAPH2 2.07 0.0002 0.0179
CD96 2.37 0.0000 0.0040 AFAP1L2 2.06 0.0006 0.0355
LCK 2.37 0.0000 0.0060 TOX2 2.05 0.0007 0.0393
CD247 2.34 0.0000 0.0053 PYHIN1 2.03 0.0000 0.0047
BCL11B 2.33 0.0000 0.0059 GPR18 2.03 0.0001 0.0101
ABCD2 2.31 0.0000 0.0054 KIAA0125 2.02 0.0001 0.0132
ACR, acute cellular rejection; FC, fold change.
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performance
We sought to develop a stable and economic classification
model for acute rejection based on our candidate list of dif-
ferentially expressed target genes (Table 2). Subjects were
randomly split 70:30 into a training set and a testing set.
After elimination of the redundant/correlated genes byTable 3 Gene Ontology: Top Biological Processes Enriched With ACR
Term Fold enrichment Genes p-value FDR
Immune response 9.8 CXCL12, CD27, FASLG, CTLA4, GZMB, GZMH 0.00028 0.0037
Adaptive immune response 24.1 SH2D1A, CTLA4, IFNG, KLRK1 0.00055 0.0071
T-cell receptor signaling pathway 44.3 CD27, CD3E, IFNG 0.00190 0.0250
Inflammatory response 8.7 CXCL13, CXCR3, CXCR6, CD27, AFAP1L2 0.00220 0.0290
ACR, acute cellular rejection; FDR, false discovery rate.recursive feature elimination, we developed a final logistic
regression model in the training set that maximized AUC
and required only 4 genes: thymocyte selection−associated
high mobility group box protein (TOX), sterile alpha motif
domain−containing 3 (SAMD3), interleukin 32 (IL32), and
killer cell lectin-like receptor K1 (KLRK1). This 4-gene
model achieved an AUC of 0.72 in the training set
(Figure 3a). We then defined a classification threshold that
Table 4 KEGG Pathways Enriched With ACR
Term Fold enrichment Genes p-value FDR
T-cell receptor signaling pathway 21.5 CD247, CD3e, CD8a, CD8b, GRAP2, ITK,
LCK, CTLA4, IFNG, PDCD1, ZAP70
2.70E-11 2.90E-10
Natural killer cell−mediated cytotoxicity 17.2 CD247, FASLG, LCK, SH2D1A, GZMB,
IFNG, KLRK1, PRF1, ZAP70
2.40E-08 2.60E-07
Primary immunodeficiency 27.9 CD3E, CD8A, CD8B, LCK, ZAP70 2.40E-05 2.60E-04
Cell adhesion molecules 8.7 CD8a, CD8b, TIGIT, CTLA4, PDCD1, VCAM1 4.90E-04 0.0052
Cytokine−cytokine receptor interaction 6.5 CXCL13, CXCR3, CXCR6, FASLG, IFNG, IL2RB 4.90E-04 0.0052
Graft-versus-host disease 24.3 FASLG, GZMB, IFNG, PRF1 5.10E-04 0.0055
Allograft rejection 22.4 FASLG, GZMB, IFNG, PRF1 6.60E-04 0.0070
ACR, acute cellular rejection; FDR, false discovery rate; KEGG, Kyoto Encyclopedia of Genes and Genomes.
Weigt et al. Gene Expression During Acute Rejection 851favored specificity (76%) over sensitivity (54%), which
yielded 70% classification accuracy (Figure 3b). In the
independent test set of 54 samples, the model exhibited
similar performance with an AUC of 0.72 (Figure 3c). The
performance of the classification threshold was also similar
to the training set, with specificity of 82%, sensitivity of
60%, and accuracy of 76% (Figure 3d).
In the total cohort (training and testing sets combined),
the proportion of TBBX A-grade ACR classified as ACRFigure 3 Acute cellular rejection (ACR) classification of bronchoal
model. (a) Receiver operator characteristic (ROC) curve of classifier per
predicted probability of ACR divided by 0.261) are plotted on the y ax
denotes the classification threshold between ACR and no ACR classific
diagnoses are provided for each subject on the x axis. Black closed circl
vors. Gray triangles pointing up represent subjects developing CLAD wi
jects who died within 1 year of sample. (c) ROC curve of classifier perfo
54 subject testing set. AUC, area under the curve.by our genomic analysis model increased with increasing
A-grade (Figure 4). Similarly, 100% (6/6) of SSAR cases
were classified as ACR in our model, compared with 56.2%
(18/32) of A-grade ACR cases that were non-SSAR
(p = 0.067).
Furthermore, classification as ACR by genomic analysis
was also associated with worse CLAD-free survival over the
1-year follow-up after biopsy (hazard ratio [HR] = 2.42 for
CLAD or death, 95% confidence interval [CI] = 1.29−4.53)veolar lavage (BAL) cell pellet (CP) gene expression by classifier
formance on 165 subject training set. (b) Classification scores (the
is for each subject. In the training set, the dashed line (score 1.0)
ation. Transbronchial biopsy (TBBX) histopathology or infection
es represent chronic lung allograft dysfunction (CLAD)-free survi-
thin 1 year of sample. Gray triangles pointing down represent sub-
rmance on the 54 subject testing set. (d) Classification scores in the
Figure 4 The proportion of subjects in each clinical category
classified as acute cellular rejection (ACR) by the genomic classi-
fier model. LB, lymphocytic bronchiolitis; SSAR, spirometrically
significant acute rejection.
Figure 5 Kaplan−Meier estimates of chronic lung allograft dysfunct
parison of CLAD-free survival following the bronchoscopy procedure fo
thology. (b) Comparison of CLAD-free survival following the bronchos
genomic classifier model. BAL, bronchoalveolar lavage.
852 The Journal of Heart and Lung Transplantation, Vol 38, No 8, August 2019(Figure 5). When follow-up was extended to 5 years post-
biopsy, CLAD-free survival remained worse in subjects clas-
sified as ACR by genomic analysis (Supplementary Figure
S2a online). By comparison, A-grade ACR diagnosed by
TBBX was neither associated with a significant difference in
1-year CLAD-free survival (HR 1.17 for CLAD or death,
95% CI = 0.59−2.30) (Figure 5) nor when follow-up was
extended to 5 years post-biopsy (Supplementary Figure 2b
online). In addition, the effect of genomic classification as
ACR on CLAD-free survival was greatest in the subset of
patients where TBBX was negative for A-grade ACR
(HR = 2.88 for CLAD or death, 95% CI = 1.32−6.14)
(Supplementary Figure S2c online).
Discussion
Given the importance of ACR as a modifiable risk factor for
CLAD, accurate diagnosis remains a priority in lung trans-
plantation. However, the current gold standard requires
TBBX, which has drawbacks including the small volume of
tissue sampled, leading to high rates of sub-optimal tissues
and sampling error. Furthermore, even when biopsy sam-
ples are considered adequate, interpretation is fraught with
high interobserver disagreement.6−8 Finally, TBBX is asso-
ciated with a small risk of major complications that may
lead to morbidity and even mortality in rare cases.5 We
hypothesized that gene expression in the BAL CP could be
used to diagnose ACR without the need for TBBX. Further-
more, BAL CP gene expression might improve upon
TBBX because BAL samples a larger volume of lung, and
a genomic classifier would remove the subjectivity ofion (CLAD)-free survival in the 1 year following biopsy. (a) Com-
r patients with or without acute cellular rejection (ACR) histopa-
copy procedure for patients classified as ACR or no ACR by the
Weigt et al. Gene Expression During Acute Rejection 853pathology interpretation. The current study demonstrates
the proof of concept that gene expression informs about
ACR pathogenesis, while also suggesting a potential utility
to diagnose ACR and risk stratify for the development of
CLAD better than TBBX.
Our primary finding is that A-grade ACR on TBBX is
associated with a characteristic gene expression profile in
BAL cells. The list of differentially expressed genes is
enriched for biological processes and pathways integral to
allograft rejection. For instance, the Kyoto Encyclopedia of
Genes and Genomes TCR signaling pathway was enriched
21.5-fold during A-grade ACR, including genes for CD8a,
CD8b, lymphocyte-specific protein tyrosine kinase (LCK),
and CD3e. CD8 acts to stabilize binding of the TCR to the
peptide-major histocompatibility complex, while also local-
izing LCK to the TCR/CD3 complex to facilitate early sig-
naling events during T-cell activation.23 We have also
previously shown that BAL CP gene expression of CD8
and LCK is associated with the development of CLAD.24
In addition, the cytokine−cytokine receptor interaction
pathway was enriched 6.5-fold and included CXCR3 and
interferon gamma. This finding is corroborated by previous
work showing that protein concentrations of the interferon
gamma−inducible CXCR3-binding chemokines in the BAL
fluid are associated with A-grade ACR and other lung
injury patterns, as well as with CLAD.25−27 Finally, enrich-
ment for pathways related to cell adhesion, NK cell−medi-
ated cytotoxicity, and allograft rejection add additional
support of the biological relevance of BAL CP gene expres-
sion during A-grade ACR.
This expression profile may be efficiently simplified to
an economical 4-gene classifier model that exhibits fair per-
formance as a diagnostic biomarker for histopathologic A-
grade ACR. We chose a threshold for the model that priori-
tized specificity over sensitivity. Our rationale was aimed
at better identifying clinically significant ACR at high risk
of progression to CLAD. Recognizing the well-described
shortcomings of TBBX, it is not surprising that our model
reclassifies cases of histopathologic A-grade ACR as no
ACR and other cases of no histopathologic A-grade ACR
as positive for ACR. The performance of this genomic clas-
sifier improved with increasing histopathologic A-grade,
for which there is reported greater observer agreement and
therefore confidence in the ACR diagnosis.6−8 In addition,
our classifier model indicated ACR for all cases of SSAR,
which is a strong risk factor for CLAD.11 Given the impor-
tance of ACR as a potentially modifiable CLAD risk factor,
our most intriguing finding is that classification indicating
ACR also discriminated risk of CLAD-free survival, espe-
cially in the year following biopsy, whereas a histopatho-
logic diagnosis of A-grade ACR did not. Finally, the
highest incidence of CLAD or death in the year after biopsy
was seen in the 37 cases where histopathology was negative
for A-grade ACR but where the genomic classifier pre-
dicted ACR. None of these cases were treated for rejection
at the time. We can hypothesize that corticosteroid treat-
ment could have reduced the risk of CLAD in this group,
but this hypothesis requires prospective evaluation in a clin-
ical trial.Our study corroborates prior smaller observational stud-
ies of gene expression during ACR.28,29 Although each
study used different methods and the specific genes associ-
ated with ACR differ somewhat, the functional relevance
of the differentially expressed genes were remarkably simi-
lar across studies. Specifically, increased gene expression
related to T-cell activation, and cytotoxicity was common
to each of these studies.28,29 These similar conclusions are
interesting, especially because our study relied on a differ-
ent platform to measure gene expression: this study used
RNASeq, whereas the prior studies used microarray. In
studies of T-cell activation, there has been a high correla-
tion of gene expression profiles between RNASeq and
microarray platforms using the same set of samples.30
However, RNASeq was superior in detecting low abun-
dance transcripts and demonstrated a broader dynamic
range than microarray, therefore allowing the detection of
more differentially expressed genes. Furthermore, perform-
ing RNASeq allows for the avoidance of technical issues
found using microarray probes (e.g., cross-hybridization,
non-specific hybridization, and limited detection range of
individual probes). In addition, RNASeq does not rely on
pre-designed detection probes; thus, there are no issues
associated with probe redundancy and annotation, which
simplifies the interpretation of the data.
Our final genomic classifier model included 4 genes:
TOX, SAMD3, IL32, and KLRK1. TOX has been shown to
be upregulated by calcineurin-mediated TCR signaling dur-
ing CD4 T-cell lineage development, including CD1d-
dependent NK and T regulatory CD4 T-cell sub-lineages,
and has been shown to also effect CD8 T-cell develop-
ment.31 The biological relevance of SAMD3 with allograft
rejection is not known at this time, although the Human
Protein Atlas (http://www.proteinatlas.org)32 predicts that
SAMD3 is an intracellular protein that is broadly expressed
in lymphoid tissues, especially spleen and lymph nodes. IL-
32 is expressed by IL-2−activated T cells and NK cells and
plays a role in acute graft-versus-host disease after hemato-
poietic cell transplantation.33 KLRK1 is a receptor
expressed by NK cells and cytotoxic T lymphocytes;
it mediates activation in NK cells and costimulation in
T cells.34 Collectively, this 4-gene model is consistent with
the paradigm of ACR and CLAD pathobiology. Specifi-
cally, ACR is characterized by activated immune cells
including CD4 T cells, CD8 T cells, NK cells, and NK T
cells, which drive the cytotoxicity responsible for allograft
injury that eventually leads to CLAD. Future prospective
studies should test whether this genomic classifier leads to
earlier or more appropriate treatment of ACR, an interven-
tion that might reduce CLAD.
There are limitations inherent to the design of this
study. We examined a cross-sectional selection of samples
from lung transplant recipients at a single center. It would
be valuable to include longitudinal sampling to character-
ize the evolution of gene expression before and after ACR
and through the development of CLAD. Our study cannot
determine the effect of treatment on gene expression, and
therefore, we do not know whether knowledge of gene
expression can impact outcomes. Although our study
854 The Journal of Heart and Lung Transplantation, Vol 38, No 8, August 2019included independent training and testing cohorts, all
patients were from a single center; future studies would
benefit from the inclusion of an external validation cohort.
We are reassured by the fact that the biological processes
and pathways enriched in our gene list are consistent with
expectations. We also acknowledge that 9% of samples
selected for inclusion were inadequate for RNASeq either
because of degraded RNA or low RNA concentrations.
This is similar to the 8% rate of inadequate TBBX reported
in lung transplant recipients.6 However, the proportion of
inadequate BAL samples for RNASeq could probably be
reduced to nearly 0% with the use of RNA stabilization sol-
utions and RNASeq library construction kits designed for
low input. Finally, although a BAL CP genomic classifier
test could reduce the complications associated with TBBX,
it does not eliminate the need for invasive bronchoscopy. It
is unclear whether the findings in the BAL CP would also
be observed in peripheral blood.
In summary, we showed that BAL CP gene expression
during histopathologic A-grade ACR is enriched for
immune responses including TCR signaling, cytokine sig-
naling, cell adhesion, and cytotoxicity. Gene expression to
diagnose ACR could be a less invasive alternative to
TBBX. In fact, we found that differential gene expression
can be simplified to a 4-gene signature with fair perfor-
mance as a surrogate for TBBX, but with potentially greater
clinical implications. This study demonstrates proof of con-
cept that BAL CP gene expression informs about the patho-
genesis of ACR and risk of CLAD. A multicenter study is
required to establish whether BAL CP gene expression
could reduce or eliminate the need for TBBX to diagnose
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